HomeABCL • NASDAQ
add
AbCellera Biologics Inc
Previous close
$3.64
Day range
$3.64 - $3.76
Year range
$1.89 - $6.52
Market cap
1.12B USD
Avg Volume
4.85M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 8.96M | 37.62% |
Operating expense | 30.20M | -48.98% |
Net income | -57.12M | -11.76% |
Net profit margin | -637.84 | 18.79% |
Earnings per share | -0.19 | -11.76% |
EBITDA | -71.03M | -25.18% |
Effective tax rate | 16.94% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 495.67M | -22.93% |
Total assets | 1.36B | -2.64% |
Total liabilities | 391.95M | 24.54% |
Total equity | 964.04M | — |
Shares outstanding | 299.34M | — |
Price to book | 1.12 | — |
Return on assets | -13.83% | — |
Return on capital | -16.91% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | -57.12M | -11.76% |
Cash from operations | -52.59M | -82.10% |
Cash from investing | 36.49M | 886.70% |
Cash from financing | 7.37M | 134.40% |
Net change in cash | -9.28M | 57.19% |
Free cash flow | -44.36M | -323.45% |
About
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
CEO
Founded
2012
Headquarters
Website
Employees
596
